




Use of routinely collected electronic healthcare data: Lessons Learned

Massoud Toussi, MD, PhD, MBA European lead, Pharmacoepidemiology and Safety Real World Evidence Solutions, IMS Health, France

ENCePP Plenary 25 November 2014 European Medicines Agency



Generating evidence from real world data



Routinely collected healthcare databases?

Healthcare data collected in routine practice

- Minimum intervention in the workflow of care giver as compared to primary data collection
- Data collection continuous, rather than study based
- Close to the real-life "reporting" practice



Examples


- Electronic medical records
- Claims
- Pharmacy dispensing data
- Survey panels
- Lab values
- Connected devices
- Patient-reported
 outcomes




Scope of this presentation

- Focus on healthcare data collected by a panel of healthcare professionals:
 - EMR
 - LRx
 - RxDx
- For each database
 - Brief explanation
 - Lessons learned
 - Frequently asked question (FAQ)


Key considerations in panel design



Electronic medical records (EMR)



Working with EMR data: lessons learned



6

FAQ: What about representativeness?

Comparison of diabetes patients in 2005 by age group


Patient age	GEK patients	Disease Analyzer patients (n = 12,533)			
	(%)	%	95% CI		
≤39	11.4	12.1	(10.7-13.4)		
40-49	14.3	15.9	(14.4-17.4)		
i050-59	23.3	24.1	(22.3-25.9)		
60-69	27.0	27.0	(25.2-28.9)		
70-79	17.8	16.5	(15.0-18.1)		
>80	6.3	4.4	(3.5-5.2)		

Comparison of antihypertensive patients treated in 2005 by gender

ATC class	GEK male patients	Disease Analyzer patients (n = 2,156)			
	(%)	%	95% CI		
C03A diuretics	54.6%	53.0%	(50.2-55.8)		
C07 β-blockers	57.5%	56.4%	(54.7-58.2)		
C08 calcium-antagonists	61.3%	58.7%	(56.0-61.4)		
C09AB ACE-inhibitors	63.8%	63.8%	(62.0-65.7)		
C09CD sartans	58.6%	57.4%	(54.6-60.2)		

CI = Confidence interval Source: [Glaeske and Janhsen 2007] Important to know if the database is representative, but the importance of representativeness shall be considered in the context of the research question.

- Comparison of panel participants and non participants is not always useful/possible.




imshealth


Massoud Toussi (IMS Health) – ENCePP Plenary, 25 November 2014, European Medicines Agency

Longitudinal dispensing databases

- A representative panel of pharmacies contributes dispensing data of patients to a database
- Patients can be tracked
 - Over time
 - Across pharmacies of the panel
- Submitted information
 - Dispensing information (drugs dispensed, volumes, date, specialty of the prescriber, settings of the prescription)
 - Patient's characteristics (age, gender)



Working with LRx data: lessons learned



imshealth

9

FAQ: What about patient loyalty to pharmacies?

- Patients are less loyal to their pharmacies than to their doctors
 - Better to be checked per study
- More likely to be loyal
 - Older patients
 - Those with chronic disease
 - Those living in rural area
- Points to consider
 - Sub selection of loyal patients may cause a selection bias
 - Make sure the characteristics of loyal and non-loyal patients are similar
- Loyalty question, not specific to pharmacies
 - This question shall be asked for EMRs, Claims, etc based on the context of the health system

Number of pharmacies of the panel visited in 2013 in France	Number of patients (all categories)	% of patients
1	12 352 447	71.5%
2	3 924 534	22.7%
3	787 904	4.6%
4	170 027	1.0%
5	38 417	0.2%
6	9 678	0.1%
7	2 710	0.0%
8	830	0.0%
9	307	0.0%
10	150	0.0%
11	77	0.0%
12	40	0.0%
13	23	0.0%
14	17	0.0%
15	18	0.0%
16	4	0.0%
17	8	0.0%
18	2	0.0%
19	4	0.0%
20	2	0.0%
21	3	0.0%
22	1	0.0%
23	1	0.0%
24	3	0.0%
25	1	0.0%
31	1	0.0%
32	1	0.0%
33	1	0.0%
40	1	0.0%


Prescription-diagnosis data (RxDx)

 Systematic, cross-sectional collection of prescriptions along with diagnoses related to each prescribed drug




- One of the oldest and most widely available forms of routinely collected healthcare data
- Under-used in pharmacoepidemiology

	Physician panel stratified by region and specialty								
	Specialty	1	2	3	4	5	6	7	Total
001	General Practice	34	30	63	12	51	46	64	300
	001 General Practice	21	15	32	7	26	23	36	160
	054 Family Practice	13	15	31	5	25	23	28	140
002	Internal Medicine	4	4	12	3	8	6	8	45
003	Pediatry	6	6	14	3	13	11	12	65
006	Rheumatology	3	2	8	1	7	4	5	30
007	Gastroenterology	4	4	10	3	9	6	9	45
800	Cardiology	4	5	10	3	9	6	8	45
009	Surgery	3	3	8	1	6	4	5	30
010	Dermatology	3	3	7	1	7	4	5	30
011	Endocrinology	3	3	8	1	6	4	5	30
012	Ophthalmology	3	3	9	3	7	5	5	35
013	Gynecology	4	4	9	3	10	7	8	45
015	Odontology	4	5	9	3	8	7	9	45
016	Otorhinolaryngology	3	3	7	1	6	5	5	30
017	Traumatology	3	4	7	3	8	5	5	35
018	Urology	3	3	7	1	6	5	5	30
020	Pulmology	3	3	8	1	6	4	5	30
021	Neurology	3	3	8	1	7	4	4	30
022	Psychiatry	3	4	8	1	10	4	5	35
	Total	93	92	212	45	184	137	172	935



Working with RxDx data: lessons learned



12

FAQ: Are these reports reliable?


- Important to identify between:
 - Deviation from practice
 - Deviation from reporting rules
- Reporting problems often occur when
 - an important clinical condition or drug overshadows a less important one
 - a general practitioner renews the drugs prescribed by a specialist
- Points to consider
 - A small proportion of aberrant values reported as the reason for the prescription of a given drug: to be treated as outliers.
 - Large quantity of aberrant values: to check whether this drug is widely misused or the reporting is affected by one of the above conditions.

	LIEU DE CONSULTATION	PATIENT		CATÉGORIE	SOCIO-PR	OFESSION	NNELLE	
1906113	Cabinet Clinique	Age 64 ar(s) Sexe) Bébé_ mos Poids ((- de 24 mois)	€	Agriculteur Artisan, Commerçant Cadre supérieur Profession libérale Profession intermédiaire (administrative et commerciale)		vrier traité	 Autre A Sans profe Etudi 	activité
		TIF de CONSULTATION	revou	ellement #	- AV	С		
ette consultation	SCRIPTION(S) DE PRO	DUIT(S), avec ou sans AMM, I a question suivante "AUTRES PRESCRA			Patient	recevant pour la produit (makic	e (inc ficia ulei)	
Voue pouver join	OUI (Merci de préciser o dre l'ordonnance du patient, le rej it ent impératif de compiléter les	(-dessous) port du n° du produit sur l'ordonnance vous p Informations concernant l'initiation at le	sermettra de ne pas raco	pier les prescriptions.	En initiation d'un nouveau traitement	En remplace- ment d'un subre produit	En addition au traitement existant	Pred renou au cou cell consult
Augustanter POSOLOGIE	par prise	Préclaez le dosage cisez la forme (cp, critme,)	- <u>2</u> -	Durée totale de cette prescription → Louyte cu Lou	-	•		×
	Ka Ka	idezie 160	Antonio de primero -	→~	-	•	•	>
PRODUIT POSOLOGIE	ambre d'unitée par prise		Morebre de primes	→ Lun ^{cu} Lun	-	•	•	-
PRODUIT								
POSOLOGIE	Dombne d'Unités par prise		Nombre de prises					
N	per prise	Certificat Arrêt de t Rééducation fonctionnelle	ravail	Lenge ou Lenge Verres correcteurs / Lenf Autres (précisez) :		aploration (F		
WUTRES PRESCRIP	TIONS Courrier Biologie	Rééducation fonctionnelle	ravail		iles 🖬 E			, Scopi
AUTRES PRESCRIP Pame DIAGNOS ACTES : Traiteme ette consultation PRE:	TIONS Courrier Biologie	Rééducation fonctionnelle TIF de CONSULTATION tiqués <u>au cours</u> de DUIT(S), avec ou sans AMM, D	doule	Autres (précisez) :	nes DE		Radio, Echo	, Scopi
A AUTRES PRESCRIP 2 ^{4mm} DIAGNOS ACTES : Traiteme ette consultation PRE: Vose pourse John	TIONS Courtier Biologie Courtier Biologie CTIC ou à défaut M4 ints ou examens pra SCRIPTION(5) DE PRO + NON (Précide paréciser à + OUT (Merci de paréciser à	Rééducation fonctionnelle DTIF de CONSULTATION tiqués <u>au cours</u> de DUIT(5), avec ou sans AMM, [] guestion savance "AUTRES RESCRI		Autres (précisez) :	nes DE	xploration (F	Radio, Echo	, Scopi
A AUTRES PRESCRIP 2 ^{4mm} DIAGNOS ACTES : Traiteme ette consultation PRE: Vose pourse John	TIONS Courrier Biologie Courrier Biologie	Réducation functionnet DTIF de CONSULTATION Riqués <u>all COUITS</u> de DUIT(5), avec ou sans AMM, to outifish avance ou sans AMM, to outifish avance ou sans AMM, to outifish avance ou sans and AV/7857 MFSC500- descus) descus) descus) descus)		Autres (précisez) :	Alles DE	receivant pour la preceivant pour la preceivant (monte) 	Radio, Echo	Pred (Brook a) consult
A UTRES PRESCRIP Adme DIAGNOS CTES : Traiteme ette consultation PRE: Mas power 200 CTES : Traiteme PRE: Mas power 200 ADME PRODUIT	Courtier	Réducation functionnet TIF de CONSULTATION tiqués all COUITS de DUIT(S), svec ou sans ANH, q duit(S), svec ou s		Autres (précisez)	Patient Control Patient Contro	receivent pour la product pour la produit (molée En mensione medition autre produit	addo, Echo addis, Echo addison au tuberent addison au tuberent addison au	
utres prescript the DIAGNOS CTES : Traiteme tete consultation Pres- Visit prescript Prescript Propourt Propourt	TITON Courses	Réducation functionnet TIF de CONSULTATION tiqués all COUITS de DUIT(S), svec ou sans ANH, q duit(S), svec ou s		Autres (précisez)	Patient Pat	research poor la production (F production (Social production (Social autor production autor	Addio, Echo attra Jaia addio, Echo addio, Addio, Addio	Pred officer consult

Trimetazidine and aspirin are both associated to a treatment renewal for cerebrovascular accident. The general practitioner probably lacks details on the context in which the original prescription was made by the specialist. However, this information is recorded as-is in the database, and often interpreted as misuse.

Conclusion

- The best database is the one which is most fit-for-purpose.
 - ask how the database is made (it's story), not just what it contains.
 - run a feasibility if you are not sure about the quality and content of a database.
 - have in mind that a combination of different data sources may be the best solution



Massoud Toussi (IMS Health) – ENCePP Plenary, 25 November 2014, European Medicines Agency



Thank you!

Questions?

Massoud TOUSSI, MD, PhD, MBA Medical Director, European Lead, Pharmacoepidemiology and Safety IMS Health Tour Ariane, 5-7 place de la Pyramide, 92088 La Défense Cedex, France Tel: +33 (0)1-41 35 13 35 Mobile: +33 (0)6-07 96 66 50 Fax: +33 (0)1-41 35 13 49 email: mtoussi@fr.imshealth.com

